ArticleCancer diagnosis & prognosis
A Tissue-based Biomarker Risk Score for Predicting Survival in Pancreatic Ductal Adenocarcinoma.
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: Pancreatic cancer is a highly aggressive disease, with limited prognostic tools available for risk stratification. This study aimed to evaluate the prognostic significance of nine tissue biomarkers and develop a biomarker-based risk score for predicting patient survival. Patients and Methods: Tumor samples from 141 resected patients with pancreatic cancer were analyzed with tissue microarrays and immunohistochemistry to assess the expression levels of CA 19-9, CA 50, CA 242, CA 724, GDF15, MMP7, MUC2, TFF1, and THBS2. A Lasso-Cox regression model was used to develop a prognostic risk score and the performance of the risk score was assessed using Kaplan-Meier survival analysis and receiver operating characteristic (ROC) curves. Results: Among the nine biomarkers, CA19-9, CA50, CA242, CA724, and THBS2 were identified as significant predictors of survival in univariable analyses. A prognostic model was constructed and included CA19-9, CA724, THBS2, tumor location, resection margin status, grade, and American Joint Committee on Cancer stage. The prognostic risk score effectively stratified patients into high- and low-risk groups, demonstrating a significant difference in median survival (14.8 Conclusion: This study identifies several tissue biomarkers associated with survival and introduces an integrative risk model to stratify pancreatic cancer patients by outcomes. The model shows good discriminatory ability and may provide a basis for more personalized risk assessment and treatment planning, although additional validation is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.